Browsing Tag
amivantamab-vmjw
2 posts
Can dual-targeting therapies redefine second-line colorectal cancer treatment in 2026?
Can dual-targeting therapies like amivantamab transform second-line colorectal cancer care? Explore what’s changing and who stands to win. Read the full story.
January 12, 2026
FDA approves RYBREVANT and LAZCLUZE for EGFR-mutated advanced lung cancer
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as…
August 20, 2024